A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT01709734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Study identification
- NCT ID
- NCT01709734
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- LTN PHARMACEUTICALS, INC.
- Industry
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Interventions
- galeterone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2012
- Primary completion
- Aug 31, 2016
- Completion
- Aug 31, 2016
- Last update posted
- Mar 14, 2023
2012 – 2016
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA David Geffen School of Medicine | Los Angeles | California | 90095-7384 | — |
| San Bernardino Urological Associates | San Bernardino | California | 92404 | — |
| Raton Regional Hospital, Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Tulane Cancer Center | New Orleans | Louisiana | 70112 | — |
| AAHS Research Institute | Annapolis | Maryland | 21401 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Sidney Kimmel Johns Hopkins | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Urology Cancer Center and GU Research Network | Omaha | Nebraska | 68130 | — |
| Coastal Urology Associates | Brick | New Jersey | 08724 | — |
| Premier Urology Associates, LLC | Lawrenceville | New Jersey | 08648 | — |
| Roswell Park Center Institute | Buffalo | New York | 14263 | — |
| Mount Sinai | New York | New York | 10029 | — |
| Carolina Clinical Trials | Concord | North Carolina | 28025 | — |
| Greenville Hospital System University Medical Center | Greenville | South Carolina | 29605 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| Urology Clinics of North Texas | Dallas | Texas | 75230 | — |
| University of Washington/Seattle Cancer Care Alliance | Seattle | Washington | 98136 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01709734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01709734 live on ClinicalTrials.gov.